Drug Trial Radar · NCT02606461
Selinexor in Advanced Liposarcoma
Last checked: Nov 20, 2026Latest source record: Jan 23, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
342
Actual
Start
Jan 4, 2016
Primary completion
Oct 28, 2020
Study completion Oct 26, 2021
Sponsor
- Lead sponsor
- Karyopharm Therapeutics IncIndustry
- Sponsor type
- Industry
- First posted
- Nov 17, 2015
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2-3 study of patients diagnosed with advanced unresectable dedifferentiated liposarcoma. Approximately 342 total patients will be randomized to study treatment (selinexor or placebo).
Conditions
- Dedifferentiated Liposarcoma
Interventions
SelinexorDrug
Selinexor 60mg
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Phase 3 Double Blind: Progression-free Survival (PFS) as Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1Time frame: From the date of randomization until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
- Phase 3 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1Time frame: From the date of randomization in the Phase 3 open label period until the first date of disease progression, or death due to any cause whichever occurred first (up to 57 months)
- Phase 2 Double Blind: Progression-free Survival (PFS) as Per RECIST Version 1.1Time frame: From date of randomization until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
- Phase 2 Open Label: Progression-free Survival (PFS) as Per RECIST Version 1.1Time frame: From date of randomization in the Phase 2 open label period until the first date of PD or death due to any cause, whichever occurred first (up to 57 months)
Locations
71 sites in 10 countries. Site status is shown where the registry gives one.
Cedars-Sinai Medical Center
Los Angeles, California
University of California, Los Angeles
Los Angeles, California
Sarcoma Oncology Center
Santa Monica, California
Stanford University
Stanford, California
University of Colorado-Denver
Denver, Colorado
Yale Cancer Center
New Haven, Connecticut
Mayo Clinic
Jacksonville, Florida
Northwestern Memorial Hospital
Chicago, Illinois
Johns Hopkins
Baltimore, Maryland
Massachusetts General Hospital
Boston, Massachusetts
Dana Farber Cancer Institute
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Mayo Clinic Rochester
Rochester, Minnesota
Washington University School of Medicine
St Louis, Missouri
Columbia University Medical Center
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
Northwell Health Physicians Partners
New York, New York
Duke Institute of Cancer
Durham, North Carolina
James Cancer Center, Ohio State University
Columbus, Ohio
Oregon Health and Science
Portland, Oregon
University of Pennsylvania
Philadelphia, Pennsylvania
Fox Chase Cancer Center
Philadelphia, Pennsylvania
University of Pittsburgh Medical Center (UPMC)
Pittsburgh, Pennsylvania
Vanderbilt
Nashville, Tennessee
MD Anderson
Houston, Texas
Fred Hutchinson Cancer Research Center
Seattle, Washington
UZ Brussel
Brussels, Belgium
UCL Saint-Luc
Brussels, Belgium
UZ Gent
Ghent, Belgium
Cross Cancer Center - Alberta Health Services
Edmonton, Alberta, Canada
The Ottawa Hospital Cancer
Ottawa, Ontario, Canada
Princess Margaret Hospital
Toronto, Ontario, Canada
McGill University
Montreal, Quebec, Canada
Institut Bergonie
Bordeaux, France
Oscar Lambret Center
Lille, France
Centre Leon Berard
Lyon, France
Timone University Hospital
Marseille, France
Institut Régional du Cancer de Montpellier (ICM)
Montpellier, France
CLCC Antoine Lacassagne
Nice, France
Institut Curie
Paris, France
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.